This phase Ib/II trial aims to explore the safety, tolerability, and anti-tumour activity of a targeted cancer therapy in patients with breast cancer that has not previously been treated using chemotherapy and has spread to other parts of the body .
This trial is treating patients with HER2-positive Metastatic Breast Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)
The study will consist of 2 phases: a dose escalation phase (Part 1) and a dose expansion phase (Part 2). Part 1 of each module will enrol patients with locally assessed HER2-positive advanced/MBC in second-line or later. Part 2 of each module will enrol patients with locally assessed HER2-positive breast cancer who have not received prior treatment for advanced/metastatic disease.
Recruiting Hospitals Read More